ozempic semaglutide breast cancer risk Weight loss drugs could prevent cancer, preliminary Penn Medicine research shows GLP-1 drugs have entered the

Are your hormones to blame

Food and Drug Administration approved the semaglutide injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity

GLP-1 Weight Management $151 per month .25 mg, .5 mg, 1 mg, 2 mg *This estimate derives from Novo Nordisk's Phase 3 clinical trial results which showed 14.9% average weight loss over 68 weeks among people utilized a maximum tolerated dose of 2.4 mg once-weekly

While effective for weight loss and managing blood sugar, it can cause some side effects, especially when you first start taking it or if the dose is increased

Have Skin Sensitivities: Transdermal patches require direct skin contact for extended periods